Susquehanna International Group
INDV icon

Susquehanna International Group’s Indivior Pharmaceuticals INDV Stock Holding History

Susquehanna International Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.88M Buy
160,097
+111,412
+229% +$3.68M ﹤0.01% 4270
2025
Q4 		$1.75M Sell
48,685
-553,378
-92% -$16.9M ﹤0.01% 5926
2025
Q3 		$14.5M Buy
602,063
+115,176
+24% +$2.41M ﹤0.01% 2541
2025
Q2 		$7.18M Sell
486,887
-1,785,055
-79% -$20.8M ﹤0.01% 3338
2025
Q1 		$21.7M Buy
2,271,942
+2,050,248
+925% +$21.6M ﹤0.01% 1679
2024
Q4 		$2.76M Sell
221,694
-6,199
-3% -$63.8K ﹤0.01% 4632
2024
Q3 		$2.22M Sell
227,893
-8,159
-3% -$95.6K ﹤0.01% 5061
2024
Q2 		$3.81M Buy
236,052
+34,459
+17% +$622K ﹤0.01% 3890
2024
Q1 		$4.32M Buy
201,593
+175,773
+681% +$3.3M ﹤0.01% 3878
2023
Q4 		$395K Hold
25,820
– – ﹤0.01% 9225
2023
Q3 		$583K Buy
+25,820
New +$589K ﹤0.01% 7874

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's INDV Position: Q1 2026 in Review

Susquehanna International Group increased its Indivior Pharmaceuticals (INDV) stake by 229% in Q1 2026, buying an estimated $3.68M and bringing the position to 160,097 shares worth $4.88M. The position accounts for ﹤0.01% of the portfolio, ranked #4270.

Susquehanna International Group first reported a position in INDV in Q3 2023 and has held it in 11 quarters since. The position peaked at $21.7M in Q1 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Susquehanna International Group held 160,097 shares of Indivior Pharmaceuticals worth $4.88M as of Q1 2026.
  • Susquehanna International Group bought 111,412 Indivior Pharmaceuticals shares in Q1 2026, an estimated $3.68M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4270 holding.
  • Susquehanna International Group first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Susquehanna International Group's Indivior Pharmaceuticals position peaked at $21.7M in Q1 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.